Arbutus Biopharma Corp (ABUS)


Stock Price Forecast

May 24, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Arbutus Biopharma Corp chart...

About the Company

Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.

Sector

Life Sciences

Industry

Pharmaceutical Preparations

Employees

106

Exchange

Nasdaq

$12M

Total Revenue

106

Employees

$593M

Market Capitalization

-7.50

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ABUS News

We don't have any news on Arbutus Biopharma Corp at the moment.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...